Skip to content
Back to meeting Original
Targeted Oncology· @TargetedOnc · X·· 1 day agoScore70

KRASCENDO

Body

ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials in lung and gastrointestinal cancers. #ESMO26
https://www.targetedonc.com/view/esmo-2026-savolitinib-presidential-symposium-divarasib-nsclc-krascendo1-saffron-clarity-gastric01-harmoni-gi1

25 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

Source: Targeted Oncology · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.